- Home
- LPL vs TARS Comparison
LPL vs TARS Comparison
Compare LPL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPL | TARS |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPL | TARS |
|---|---|---|
| Price | $3.31 | $70.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.9M | 708.6K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $1.35 | $56.43 |
| Revenue Next Year | $2.94 | $30.19 |
| P/E Ratio | $25.64 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $2.76 | $48.20 |
| 52 Week High | $5.83 | $85.25 |
Technical Indicators
Market Signals| Indicator | LPL | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 63.61 |
| Support Level | $2.76 | $60.95 |
| Resistance Level | $4.37 | $73.45 |
| Average True Range (ATR) | 0.10 | 3.29 |
| MACD | 0.04 | 0.84 |
| Stochastic Oscillator | 46.96 | 83.31 |
Price Performance
Historical ComparisonAbout LPL LG Display Co Ltd AMERICAN DEPOSITORY SHARES
LG Display Co Ltd manufacture TFT-LCD and OLED technology-based display panels in a broad range of sizes and specifications mainly for use in IT products (comprising notebook computers, desktop monitors and tablet computers), televisions, mobile devices, including smartphones, as well as auto products, and it are one of the world's suppliers of large-sized OLED television panels. It also manufacture display panels for industrial and other applications, including entertainment systems and medical diagnostic equipment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.